Literature DB >> 25591327

Stereotactic radiotherapy in the treatment of primary bronchial carcinoid tumor.

Rovel J Colaco1, Roy H Decker2.   

Abstract

Entities:  

Keywords:  Carcinoid; Neuroendocrine Tumor; SABR; SBRT; Stereotactic body radiotherapy

Mesh：

Year:  2014        PMID： 25591327     DOI： 10.1016/j.cllc.2014.12.005

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  5 in total

1.  Prognosis of patients with primary malignant main stem bronchial tumors: 7,418 cases based on the SEER database.

Authors:  Ke Ma; Fenghao Sun; Xiaodong Yang; Shuai Wang; Lin Wang; Yulin Jin; Yu Shi; Wei Jiang; Cheng Zhan; Qun Wang
Journal:  Onco Targets Ther       Date:  2017-12-22       Impact factor: 4.147

2.  Assessment of the prognostic factors in patients with pulmonary carcinoid tumor: a population-based study.

Authors:  Yiwei Huang; Xiaodong Yang; Tao Lu; Ming Li; Mengnan Zhao; Xingyu Yang; Ke Ma; Shuai Wang; Cheng Zhan; Yu Liu; Qun Wang
Journal:  Cancer Med       Date:  2018-05-07       Impact factor: 4.452

3.  Stereotactic body radiation therapy versus fractionated radiation therapy for early-stage bronchopulmonary carcinoid.

Authors:  Rodney E Wegner; Stephen Abel; Zachary D Horne; Shaakir Hasan; Athanasios Colonias; Vivek Verma
Journal:  Lung Cancer Manag       Date:  2019-08-21

4.  The Cancers-Specific Survival of Metastatic Pulmonary Carcinoids and Sites of Distant Metastasis: A Population-Based Study.

Authors:  Jiandong Zhang; Qiongjie Yu; Yi He; Tingting Hu; Kun Chen; Zhihao Yang; Xingbo Zhang; Dezhi Cheng; Zhifeng He
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

Review 5.  The Role of Conventionally Fractionated Radiotherapy and Stereotactic Radiotherapy in the Treatment of Carcinoid Tumors and Large-Cell Neuroendocrine Cancer of the Lung.

Authors:  Mateusz Bilski; Paulina Mertowska; Sebastian Mertowski; Marcin Sawicki; Anna Hymos; Paulina Niedźwiedzka-Rystwej; Ewelina Grywalska
Journal:  Cancers (Basel)       Date:  2021-12-30       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.